Therapeutic HPV-16 Vaccination for the Treatment of Anal Dysplasia (VACCAIN-T)
Therapeutic Vaccination Against Human Papillomavirus Type 16 for the Treatment of Anal Intraepithelial Neoplasia in HIV+ Men
Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Listed as NCT01923116, this PHASE1/PHASE2 trial focuses on Anal Intraepithelial Neoplasia and HIV and remains completed. Sponsored by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), it has been updated 6 times since 2013, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE1_PHASE2
-
Apr 2018 — Jun 2018 [monthly]
Completed PHASE1_PHASE2
Status: Recruiting → Completed
▶ Show 1 earlier version
-
Jan 2017 — Apr 2018 [monthly]
Recruiting PHASE1_PHASE2
First recorded
Aug 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- ISA Pharmaceuticals B.V.
- Leiden University Medical Center
For direct contact, visit the study record on ClinicalTrials.gov .